AHCPR GUIDELINE ON MANAGEMENT OF CANCER-RELATED
Executive Summary
AHCPR GUIDELINE ON MANAGEMENT OF CANCER-RELATED PAIN in clinical practice is currently targeted for release this autumn, HHS' Agency for Health Care Policy and Research said. The agency has 15 clinical practice guidelines on its schedule for dissemination in 1993 and 1994. Guidelines on the initial evaluation and early treatment of HIV-positive individuals, and on the treatment and diagnosis of benign prostatic hyperplasia are anticipated to be out this summer. Farthest along is a guide on sickle cell disease in newborns and infants, which is scheduled for release April 27. Among the documents to be unveiled in 1993 is a guideline for primary care physicians covering otitis media in children. There has been some debate about the effectiveness of current treatments for otitis media, which include antibiotics, tubal insertions and surgery. Critics of current treatment practices include Erdem Cantekin, PhD, University of Pittsburgh, while other experts defend the use of the therapies. The panel creating the otitis media guideline held a public hearing in May 1992 ("The Pink Sheet" June 1, 1992, T&G-14). Other guides targeted for release some time this year cover the care and evaluation of heart failure; lower back problems (anticipated to be ready in the late summer/early fall); post- stroke rehabilitation; screening for Alzheimer's and related dementias; treatment of pressure ulcers in adults; and quality determinants of mammography. Next year, the HHS agency hopes to have ready clinical practice guidelines on chest pain due to unstable angina; cardiac rehabilitation services; anxiety and panic disorders in primary care; and smoking prevention and cessation. The agency recently released its fifth guideline, which covers depression in the primary care setting ("The Pink Sheet" April 19, p. 8).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth